Abstract
This review highlights the potential benefits and challenges of the application of Hematopoietic Cell Therapy (HCT) to the treatment of three rare genetic conditions affecting immunohematopoiesis early in life: IPEX (Immune dysregulation, Polyendocrinopathy, X-linked), ALPS (Autoimmune Lymphoproliferative s.), and Dyskeratosis Congenita (DC). Each of these conditions can result from several distinct genetic defects with somewhat distinct clinical prognoses. Severe, life-threatening, autoimmune complications are seen with IPEX and ALPS. In the DC disorders, marrow failure is a common abnormality. ALPS and DC are associated with increased risk of hematopoietic malignancy. Early experience with HCT in these disorders predict that most of the life-threatening complications of these conditions are reversible and/or preventable by HCT. In the current era, it is advised that affected patients undergo definitive genetic diagnosis, and be considered for reduced intensity HCT when young and relatively healthy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.